271 related articles for article (PubMed ID: 28057719)
1. Structure and inhibitor specificity of the PCTAIRE-family kinase CDK16.
Dixon-Clarke SE; Shehata SN; Krojer T; Sharpe TD; von Delft F; Sakamoto K; Bullock AN
Biochem J; 2017 Feb; 474(5):699-713. PubMed ID: 28057719
[TBL] [Abstract][Full Text] [Related]
2. Cyclin Y phosphorylation- and 14-3-3-binding-dependent activation of PCTAIRE-1/CDK16.
Shehata SN; Deak M; Morrice NA; Ohta E; Hunter RW; Kalscheuer VM; Sakamoto K
Biochem J; 2015 Aug; 469(3):409-20. PubMed ID: 26205494
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase 16/PCTAIRE kinase 1 is activated by cyclin Y and is essential for spermatogenesis.
Mikolcevic P; Sigl R; Rauch V; Hess MW; Pfaller K; Barisic M; Pelliniemi LJ; Boesl M; Geley S
Mol Cell Biol; 2012 Feb; 32(4):868-79. PubMed ID: 22184064
[TBL] [Abstract][Full Text] [Related]
4. Orphan kinases turn eccentric: a new class of cyclin Y-activated, membrane-targeted CDKs.
Mikolcevic P; Rainer J; Geley S
Cell Cycle; 2012 Oct; 11(20):3758-68. PubMed ID: 22895054
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel PCTAIRE-1/CDK16 substrates using a chemical genetic screen.
Shehata SN; Deak M; Collodet C; Spiegl SF; Geley S; Sumpton D; Sakamoto K
Cell Signal; 2019 Jul; 59():53-61. PubMed ID: 30880224
[TBL] [Abstract][Full Text] [Related]
6. Analysis of substrate specificity and cyclin Y binding of PCTAIRE-1 kinase.
Shehata SN; Hunter RW; Ohta E; Peggie MW; Lou HJ; Sicheri F; Zeqiraj E; Turk BE; Sakamoto K
Cell Signal; 2012 Nov; 24(11):2085-94. PubMed ID: 22796189
[TBL] [Abstract][Full Text] [Related]
7. Phosphoregulation of the oncogenic protein regulator of cytokinesis 1 (PRC1) by the atypical CDK16/CCNY complex.
Hernández-Ortega S; Sánchez-Botet A; Quandt E; Masip N; Gasa L; Verde G; Jiménez J; Levin RS; Rutaganira FU; Burlingame AL; Wolfgeher D; Ribeiro MPC; Kron SJ; Shokat KM; Clotet J
Exp Mol Med; 2019 Apr; 51(4):1-17. PubMed ID: 30992425
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex.
Jeffrey PD; Russo AA; Polyak K; Gibbs E; Hurwitz J; Massagué J; Pavletich NP
Nature; 1995 Jul; 376(6538):313-20. PubMed ID: 7630397
[TBL] [Abstract][Full Text] [Related]
9. New structural insights into phosphorylation-free mechanism for full cyclin-dependent kinase (CDK)-cyclin activity and substrate recognition.
Zheng F; Quiocho FA
J Biol Chem; 2013 Oct; 288(42):30682-30692. PubMed ID: 24022486
[TBL] [Abstract][Full Text] [Related]
10. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
[TBL] [Abstract][Full Text] [Related]
11. The roles, molecular interactions, and therapeutic value of CDK16 in human cancers.
Wang X; Liu R; Li S; Xia W; Guo H; Yao W; Liang X; Lu Y; Zhang H
Biomed Pharmacother; 2023 Aug; 164():114929. PubMed ID: 37236028
[TBL] [Abstract][Full Text] [Related]
12. CDK16 promotes the progression and metastasis of triple-negative breast cancer by phosphorylating PRC1.
Li X; Li J; Xu L; Wei W; Cheng A; Zhang L; Zhang M; Wu G; Cai C
J Exp Clin Cancer Res; 2022 Apr; 41(1):149. PubMed ID: 35449080
[TBL] [Abstract][Full Text] [Related]
13. CCNYL1, but Not CCNY, Cooperates with CDK16 to Regulate Spermatogenesis in Mouse.
Zi Z; Zhang Z; Li Q; An W; Zeng L; Gao D; Yang Y; Zhu X; Zeng R; Shum WW; Wu J
PLoS Genet; 2015 Aug; 11(8):e1005485. PubMed ID: 26305884
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 3-Amino-1
Amrhein JA; Berger LM; Tjaden A; Krämer A; Elson L; Tolvanen T; Martinez-Molina D; Kaiser A; Schubert-Zsilavecz M; Müller S; Knapp S; Hanke T
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499165
[TBL] [Abstract][Full Text] [Related]
15. CDK1 structures reveal conserved and unique features of the essential cell cycle CDK.
Brown NR; Korolchuk S; Martin MP; Stanley WA; Moukhametzianov R; Noble MEM; Endicott JA
Nat Commun; 2015 Apr; 6():6769. PubMed ID: 25864384
[TBL] [Abstract][Full Text] [Related]
16. Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313.
Talapati SR; Nataraj V; Pothuganti M; Gore S; Ramachandra M; Antony T; More SS; Krishnamurthy NR
Acta Crystallogr F Struct Biol Commun; 2020 Aug; 76(Pt 8):350-356. PubMed ID: 32744246
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of indirubin analogues as phosphorylase kinase inhibitors.
Begum J; Skamnaki VT; Moffatt C; Bischler N; Sarrou J; Skaltsounis AL; Leonidas DD; Oikonomakos NG; Hayes JM
J Mol Graph Model; 2015 Sep; 61():231-42. PubMed ID: 26364215
[TBL] [Abstract][Full Text] [Related]
18. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
Kalra S; Joshi G; Munshi A; Kumar R
Eur J Med Chem; 2017 Dec; 142():424-458. PubMed ID: 28911822
[TBL] [Abstract][Full Text] [Related]
19. Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity.
Premnath PN; Craig SN; Liu S; Anderson EL; Grigoroudis AI; Kontopidis G; Perkins TL; Wyatt MD; Pittman DL; McInnes C
J Med Chem; 2015 Jan; 58(1):433-42. PubMed ID: 25454794
[TBL] [Abstract][Full Text] [Related]
20. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
Nandha Premnath P; Craig S; McInnes C
J Vis Exp; 2015 Oct; (105):e52441. PubMed ID: 26554946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
